Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study

Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study

A recent phase 3 trial showed that the outcome of patients with relapsed/refractory (R/R) <i>FLT3</i>-mutated acute myeloid leukemia (AML) improved with gilteritinib, a single-agent second-generation FLT3 tyrosine kinase inhibitor (TKI), compared with standard of care. In this trial, the...

Full description

Bibliographic Details
Main Authors: Sarah Bertoli, Pierre-Yves Dumas, Emilie Bérard, Laetitia Largeaud, Audrey Bidet, Eric Delabesse, Suzanne Tavitian, Noémie Gadaud, Thibaut Leguay, Harmony Leroy, Jean-Baptiste Rieu, Jean-Philippe Vial, François Vergez, Nicolas Lechevalier, Isabelle Luquet, Emilie Klein, Audrey Sarry, Anne-Charlotte De Grande, Christian Récher, Arnaud Pigneux
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
acute myeloid leukemia
<i>flt3</i>-itd mutation
<i>flt3</i>-tkd mutation
primary induction failure
refractory
relapse
tyrosine kinase inhibitors
gilteritinib
Online Access:https://www.mdpi.com/2072-6694/12/4/773

Similar Items

Similar Items